Angiotensin II antagonists – therapeutic benefits spanning the cardiovascular disease continuum from hypertension to heart failure and diabetic nephropathy

Author： Ribeiro Artur Beltrame  

Publisher： Informa Healthcare

ISSN： 1473-4877

Source： Current Medical Research and Opinion, Vol.22, Iss.1, 2006-01, pp. : 1-16

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Progression from Hypertension to Heart Failure

By  

Cardiology, Vol. 92, Iss. 1, 1999-12 ,pp. : 10-19

Karger

Access to resources Recommend Favorite

Serum Levels of the Advanced Glycation End Products Nε-Carboxymethyllysine and Pentosidine Are Not Influenced by Treatment with the Angiotensin Receptor II Type 1 Blocker Irbesartan in Patients with Type 2 Diabetic Nephropathy and Hypertension

By  

Nephron Clin Pract, Vol. 108, Iss. 4, 2008-04 ,pp. : c291-c297

Karger

Access to resources Recommend Favorite

Third‐Generation Beta‐Adrenoceptor Antagonists in the Treatment of Hypertension and Heart Failure

By  

BASIC AND CLINICAL PHARMACOLOGY & TOXICOLOGY (ELECTRONIC), Vol. 117, Iss. 1, 2015-07 ,pp. : 5-14

John Wiley & Sons Inc

Access to resources Recommend Favorite

Management of hypertension and heart failure in patients with Addison's disease

By  

CLINICAL ENDOCRINOLOGY, Vol. 82, Iss. 6, 2015-06 ,pp. : 789-792

John Wiley & Sons Inc

Access to resources Recommend Favorite

Candesartan cilexetil – a review of effects on cardiovascular complications in hypertension and chronic heart failure

By Meredith Peter A.  

Current Medical Research and Opinion, Vol. 23, Iss. 7, 2007-07 ,pp. : 1693-1705

Informa Healthcare

Access to resources Recommend Favorite